Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors
SINGAPORE and UNITED STATES — 22 JULY 2026 — Tikva Allocell today announced the successful closing of an $8 million Series A financing round, led by Kantharos Capital. The capital will accelerate the development of Tikva’s novel off-the-shelf, engineered allogeneic T-cell platform designed to tackle persistent challenges in solid tumor oncology. The funding will primarily support …